Amylyx Pharmaceuticals (AMLX) Interest & Investment Income (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Interest & Investment Income of $2.6 million for Q1 2026, up 15.19% year-over-year from $2.2 million in Q1 2025, and down 21.88% quarter-over-quarter from $3.3 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Interest & Investment Income (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Interest & Investment Income history runs 6 years deep, the most recent figure standing at $2.6 million for Q1 2026.
- In Q1 2026, Interest & Investment Income rose 15.19% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $9.6 million (down 17.7% YoY), while the FY2025 annual figure was $9.3 million, down 32.64% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $2.6 million, down from $3.3 million in the prior quarter.
- The five-year high for Interest & Investment Income was $4.4 million in Q4 2023, with the low at $131000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $3.1 million (2024), against an average of $2.7 million.
- The sharpest annual moves came in 2022 and 2025: Interest & Investment Income soared 40100.0% in 2022, then tumbled 51.83% in 2025.
- Amylyx Pharmaceuticals' Interest & Investment Income stood at $3.2 million in 2022, then surged by 38.45% to $4.4 million in 2023, then tumbled by 47.01% to $2.3 million in 2024, then soared by 42.06% to $3.3 million in 2025, then slipped by 21.88% to $2.6 million in 2026.
- Business Quant data shows AMLX's Interest & Investment Income at $2.6 million in Q1 2026, $3.3 million in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | - |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | - |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 154.39 Mn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 31.50 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 12.40 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | - |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | - |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - | 2.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.32 Mn |
| Mar 31, 2026 | 2.57 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 1.82 Mn |
| Jun 30, 2025 | 1.96 Mn |
| Mar 31, 2025 | 2.23 Mn |
| Dec 31, 2024 | 2.32 Mn |
| Sep 30, 2024 | 3.10 Mn |
| Jun 30, 2024 | 4.07 Mn |
| Mar 31, 2024 | 4.33 Mn |
| Dec 31, 2023 | 4.37 Mn |
| Sep 30, 2023 | 4.18 Mn |
| Jun 30, 2023 | 3.89 Mn |
| Mar 31, 2023 | 3.72 Mn |
| Dec 31, 2022 | 3.16 Mn |
| Sep 30, 2022 | 601,000.00 |
| Jun 30, 2022 | 402,000.00 |
| Mar 31, 2022 | 131,000.00 |
| Dec 31, 2021 | 30,000.00 |
| Sep 30, 2021 | 3,000.00 |